Atezolizumab

Research use only, not for human use.

Atezolizumab anti-PD-L1) is a fully humanized IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1 but not the interaction of PD-L2 with PD-1.

Atezolizumab anti-PD-L1) is a fully humanized IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1 but not the interaction of PD-L2 with PD-1.

Atezolizumab (0, 2.5, 5, 10, 20, and 40?μg/ml; 24 hours; HOS and 143B cells) inhibits proliferation and induces immune-independent apoptosis of osteosarcoma cells.Atezolizumab impairs the function of mitochondria to cause the imbalance between oxidants and antioxidants. Atezolizumab induces mitochondria-related apoptosis of osteosarcoma cells by activating JNK pathway. Atezolizumab (10?μg/ml; 24?hours; HOS and 143B cells) induces autophagy in osteosarcoma cells.

——

——

Others

Other Targets

Other Targets

——

——

1380723-44-3

145 kDa

——

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years